MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ
11.59
+0.61
+5.56%
After Hours: 12.59 +1 +8.63% 19:25 05/12 EDT
OPEN
11.53
PREV CLOSE
10.98
HIGH
12.22
LOW
11.38
VOLUME
696.83K
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
8.04
MARKET CAP
314.33M
P/E (TTM)
-3.8662
1D
5D
1M
3M
1Y
5Y
1D
Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)
TipRanks · 9h ago
*Arcturus Therapeutics: Prioritization of mRNA Therapeutics Pipeline Extends Cash Runway Into 2028 >ARCT
Dow Jones · 9h ago
Arcturus Therapeutics GAAP EPS of -$0.52 beats by $0.66, revenue of $29.38M beats by $6.03M
Seeking Alpha · 9h ago
BRIEF-Arcturus Therapeutics Q1 Operating Income USD -16.826 Million Vs. IBES Estimate USD -41.6 Million
Reuters · 9h ago
*Arcturus Therapeutics 1Q Loss $14.1M >ARCT
Dow Jones · 9h ago
*Arcturus Therapeutics 1Q Loss/Shr 52c >ARCT
Dow Jones · 9h ago
*Arcturus Therapeutics 1Q Rev $29.4M >ARCT
Dow Jones · 9h ago
Press Release: Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Dow Jones · 9h ago
More
About ARCT
More
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Recently
Symbol
Price
%Change

Webull offers Arcturus Therapeutics Holdings Inc stock information, including NASDAQ: ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.